342.50 +6.82 (2.03%)
Pre-Market: 8:01AM EDT
|Bid||341.06 x 100|
|Ask||342.00 x 100|
|Day's Range||333.17 - 344.37|
|52 Week Range||244.28 - 344.37|
|PE Ratio (TTM)||22.03|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Biogen eyes therapies for Parkinson's, Alzheimer's and more using biomarkers, biological mechanisms and other cutting-edge technologies.
Credit Suisse's Alethia Young and her team take a look at the biotech sector ahead of earnings, writing that they expect large-cap companies' strength to continue through the end of the year. Young writes that she expects most companies to be either in-line or above consensus estimates when they report third-quarter results, as large cap biotechs have been strong heading into t he third quarter. Among stocks where she has the most conviction in the quarter, she thinks that Biogen (BIIB) can beat expectations thanks to Spinraza (it's spinal muscular atrophy drug) trends in the U.S. She writes that she thinks investors should expect a "solid" quarter from Bioverativ (BIVV) as well, and will also be focusing on sales from Regeneron's (REGN) Dupixent and Gilead's (GILD) HCV franchise.
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $6.14 billion.
Of the 29 analysts covering Biogen (BIIB) in October 2017, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” and 11 analysts recommended a “hold.” Biogen didn't receive any “sell” ...
Biogen (BIIB) was one of the top gainers in the S&P 500 on October 5. After trading with mixed sentiment in the first three trading days of the week, Biogen opened higher on Thursday.
Biotech is booming. After particularly rough endings to 2015 and 2016, iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) has had “a rockstar of a year,” and the last two weeks, in particular, have ...
Yesterday, Celgene Corporation (NASDAQ:CELG) caught a downgrade and the stock fell 4% on the headline. To do this, I use CELG options instead of trading its underlying equity. Click to Enlarge Fundamentally, Celgene is not cheap.
Biogen (BIIB:Nasdaq) By Morgan Stanley ($314.92, Oct. 5, 2017) We are upgrading Biogen to Overweight from Equal-weight and raising the price target to $375 from $311, as we believe the base business is proving more durable than expected with Ocrevus share loss slower than expected. Business development provides upside optionality while Alzheimer’s remains the key, must-own catalyst. Biogen (BIIB) has been a complicated story with uncertainty about its base business, which is facing potential market share and pricing pressure offset by a Phase 3 Alzheimer’s catalyst that could make all its potential issues disappear.
Morgan Stanley's Matthew Harrison and his team take a look at biotech today, writing that investors should buy Biogen (BIIB) rather than Celgene (CELG). Harrison upgraded Biogen to Overweight from Equal Weight, and raised his price target from $311 to $375, writing that the company's base business is more durable than he anticipated, as its multiple sclerosis treatment, Ocrevus, is losing market share more slowly than expected. In addition, he sees Spinraza, Biogen's spinal muscular atrophy drug, as worth potentially $4 billion, a fact that's under-appreciated by the market, and writes that the company's Alzheimer's business "remains the key, must-own catalyst.
Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves "useless."
Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.
With third-quarter earnings season just around the corner, Bernstein's Aaron (Ronny) Gal and his team take a look at the biotech sector with an eye toward upcoming reports. As for specific stocks, he has Outperform ratings on Biogen (BIIB), Allergan (AGN) and Mylan (MYL). Allergan reminded us EPS should be similar to 2Q17 ($4.02) and with hurricanes probably come close (BERN: $4.04, -4c).
The three main U.S. indexes climbed to fresh record-highs for the fourth day in a row on Thursday, fueled by gains in technology stocks including Netflix, Microsoft and Amazon.com. Nine of the 11 major ...
Morgan Stanley raises its rating for Biogen shares to overweight from equal-weight, citing the potential of its Alzheimer's therapy pipeline.